SRNE vs. OCGN, BCAB, GRTS, GRPH, CCCC, GMDA, PLX, ZURA, IVVD, and ADAP
Should you be buying Sorrento Therapeutics stock or one of its competitors? The main competitors of Sorrento Therapeutics include Ocugen (OCGN), BioAtla (BCAB), Gritstone bio (GRTS), Graphite Bio (GRPH), C4 Therapeutics (CCCC), Gamida Cell (GMDA), Protalix BioTherapeutics (PLX), Zura Bio (ZURA), Invivyd (IVVD), and Adaptimmune Therapeutics (ADAP). These companies are all part of the "biological products, except diagnostic" industry.
Sorrento Therapeutics vs.
Sorrento Therapeutics (NASDAQ:SRNE) and Ocugen (NASDAQ:OCGN) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, analyst recommendations, community ranking, media sentiment, profitability, institutional ownership, risk, dividends and earnings.
In the previous week, Ocugen had 8 more articles in the media than Sorrento Therapeutics. MarketBeat recorded 10 mentions for Ocugen and 2 mentions for Sorrento Therapeutics. Sorrento Therapeutics' average media sentiment score of 0.39 beat Ocugen's score of 0.27 indicating that Sorrento Therapeutics is being referred to more favorably in the media.
Sorrento Therapeutics has a beta of 1.95, indicating that its share price is 95% more volatile than the S&P 500. Comparatively, Ocugen has a beta of 3.83, indicating that its share price is 283% more volatile than the S&P 500.
34.5% of Sorrento Therapeutics shares are held by institutional investors. Comparatively, 37.5% of Ocugen shares are held by institutional investors. 2.6% of Sorrento Therapeutics shares are held by insiders. Comparatively, 2.8% of Ocugen shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Ocugen has a net margin of 0.00% compared to Sorrento Therapeutics' net margin of -818.22%. Ocugen's return on equity of -86.48% beat Sorrento Therapeutics' return on equity.
Ocugen has lower revenue, but higher earnings than Sorrento Therapeutics.
Sorrento Therapeutics presently has a consensus target price of $9.00, suggesting a potential upside of 3,025.00%. Ocugen has a consensus target price of $4.90, suggesting a potential upside of 958.32%. Given Sorrento Therapeutics' higher possible upside, equities analysts clearly believe Sorrento Therapeutics is more favorable than Ocugen.
Sorrento Therapeutics received 516 more outperform votes than Ocugen when rated by MarketBeat users. Likewise, 74.94% of users gave Sorrento Therapeutics an outperform vote while only 67.14% of users gave Ocugen an outperform vote.
Summary
Ocugen beats Sorrento Therapeutics on 10 of the 16 factors compared between the two stocks.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding SRNE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartMedia Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Sorrento Therapeutics Competitors List
Related Companies and Tools